Eicosanoids and renal damage in cardiometabolic syndrome. Expert Opin Drug Metab Toxicol 2008 Feb;4(2):165-74
Date
02/06/2008Pubmed ID
18248310Pubmed Central ID
PMC3348552DOI
10.1517/17425255.4.2.165Scopus ID
2-s2.0-39749161642 (requires institutional sign-in at Scopus site) 54 CitationsAbstract
BACKGROUND: Obesity, hypertension and Type 2 diabetes are major contributing factors to the increase in the number of patients that have chronic kidney disease. The clustering of visceral obesity and cardiovascular risk factors has been designated metabolic syndrome or cardiometabolic syndrome. Cardiometabolic syndrome is associated with a complex systemic inflammatory state that has been implicated in medically important complications, including endothelial dysfunction. Inflammation, endothelial dysfunction and insulin resistance are interrelated and have reciprocal relationships that link cardiovascular and metabolic diseases. Ultimately, cardiometabolic syndrome increases the risk for cardiovascular events and end-organ damage. Although the number of patients with cardiometabolic syndrome is escalating, therapeutic approaches have not been developed that provide protection to the kidney.
OBJECTIVE: The objective of this review is to provide an overview of the contribution of eicosanoids to renal damage in cardiometabolic syndrome.
RESULTS/CONCLUSION: Eicosanoids are altered in cardiometabolic syndrome and contribute to the progression of renal injury. The antihypertensive and anti-inflammatory actions of epoxides and soluble epoxide hydrolase inhibitors make these attractive eicosanoid therapeutic targets for chronic kidney disease in patients with cardiometabolic syndrome.
Author List
Imig JDMESH terms used to index this publication - Major topics in bold
AnimalsDrug Delivery Systems
Eicosanoids
Enzyme Inhibitors
Epoxide Hydrolases
Epoxy Compounds
Humans
Kidney Failure, Chronic
Metabolic Syndrome
